Janssen begins Phase III study of diabetes drug canagliflozin
Janssen Research & Development (Janssen) has started a global, multicentre CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) trial of Invokana (canagliflozin) in patients with type 2 diabetes and d…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Canagliflozin | Diabetes | Diabetes Type 2 | Endocrinology | Invokana | Pharmaceuticals | Study